Cargando…
Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission
In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554799/ https://www.ncbi.nlm.nih.gov/pubmed/36248811 http://dx.doi.org/10.3389/fimmu.2022.957407 |
_version_ | 1784806778657046528 |
---|---|
author | Zhang, Jian-Nan Gao, Yang Wang, Xin-Tong Li, Na-Na Du, Xue Tang, Yu-Jia Lai, Qi-Qi Chen, Peng-Fei Yue, Chuang-Shi Wu, Ji-Han Kang, Kai Zhao, Ming-Yan |
author_facet | Zhang, Jian-Nan Gao, Yang Wang, Xin-Tong Li, Na-Na Du, Xue Tang, Yu-Jia Lai, Qi-Qi Chen, Peng-Fei Yue, Chuang-Shi Wu, Ji-Han Kang, Kai Zhao, Ming-Yan |
author_sort | Zhang, Jian-Nan |
collection | PubMed |
description | In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission. |
format | Online Article Text |
id | pubmed-9554799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95547992022-10-13 Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission Zhang, Jian-Nan Gao, Yang Wang, Xin-Tong Li, Na-Na Du, Xue Tang, Yu-Jia Lai, Qi-Qi Chen, Peng-Fei Yue, Chuang-Shi Wu, Ji-Han Kang, Kai Zhao, Ming-Yan Front Immunol Immunology In this study, we aimed to explore whether lymphocyte–C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9554799/ /pubmed/36248811 http://dx.doi.org/10.3389/fimmu.2022.957407 Text en Copyright © 2022 Zhang, Gao, Wang, Li, Du, Tang, Lai, Chen, Yue, Wu, Kang and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Jian-Nan Gao, Yang Wang, Xin-Tong Li, Na-Na Du, Xue Tang, Yu-Jia Lai, Qi-Qi Chen, Peng-Fei Yue, Chuang-Shi Wu, Ji-Han Kang, Kai Zhao, Ming-Yan Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title | Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title_full | Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title_fullStr | Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title_full_unstemmed | Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title_short | Lymphocyte–C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission |
title_sort | lymphocyte–c-reactive protein ratio can differentiate disease severity of covid-19 patients and serve as an assistant screening tool for hospital and icu admission |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554799/ https://www.ncbi.nlm.nih.gov/pubmed/36248811 http://dx.doi.org/10.3389/fimmu.2022.957407 |
work_keys_str_mv | AT zhangjiannan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT gaoyang lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT wangxintong lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT linana lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT duxue lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT tangyujia lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT laiqiqi lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT chenpengfei lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT yuechuangshi lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT wujihan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT kangkai lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission AT zhaomingyan lymphocytecreactiveproteinratiocandifferentiatediseaseseverityofcovid19patientsandserveasanassistantscreeningtoolforhospitalandicuadmission |